You are here

Persistent Clinical Improvements, Prolonged Survival Observed in Treprostinil Study of Patients With Pulmonary Hypertension

SILVER SPRING, Md., March 11 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (NASDAQ:UTHR) announced today that data on the long-term efficacy and survival benefit of Remodulin from a multi-center European study were presented at the American College of Cardiology 53rd Annual Scientific Sessions meeting in New Orleans, Louisiana.

Jean-Luc Vachiery MD, Associate Professor of Cardiology at the Erasme Hospital in Brussels, Belgium, presented long-term data that showed persistent clinical improvements and prolonged survival in a multi-center cohort of 112 pulmonary arterial hypertension patients treated with Remodulin for up to 57 months. Dr. Vachiery reported that patients improved functional class by more than 35% and their exercise tolerance improved by more than 150 meters during the study period. The study results also showed that Remodulin's most frequent side effect -- infusion site pain -- only resulted in cessation of therapy in 2% of the study cohort and that the Remodulin dose could routinely be titrated to a therapeutic level very rapidly.

"These multi-center data provide further confirmation that Remodulin therapy offers long-term symptomatic and survival benefit to patients with pulmonary hypertension. In our experience, such data, along with the obvious safety advantages of Remodulin over intravenous Flolan, clearly signify that Remodulin can be used as a first line prostacyclin therapy for the treatment of PAH in the ever-increasing number of patients who are failing oral therapies. Furthermore Remodulin dosing should be aggressive, as our experience shows infusion pain, which dissipates over time, is not a limiting factor in the vast majority of patients; yet the treatment benefit, as with Flolan, is dose-dependant," said Dr Vachiery.

Remodulin (treprostinil sodium) Injection is approved in the United States, Israel and Canada as a continuous subcutaneous infusion for the treatment of pulmonary arterial hypertension in patients with NYHA Class II-IV symptoms, to diminish symptoms associated with exercise. Remodulin should be used only by clinicians experienced in the diagnosis and treatment of pulmonary arterial hypertension.

Source: United Therapeutics Corporation

Recent Headlines

Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Breast Cancer, Gastrointestinal Tumors Most Common Types
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
NY Hospitals Required to Implement Protocols in Suspected Cases
Overall Survival 4.3 Months’ vs. 1.5 Months for Traditional Regimens